The Effect of DDAVP Infusion on Thrombin Generation in Platelet-rich Plasma of von Willebrand Type 1 and in Mild Haemophilia A Patients
- 1 January 2000
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (10) , 638-642
- https://doi.org/10.1055/s-0037-1614080
Abstract
In von Willebrand disease (vWD) type 1 and mild haemophilia A patients we studied the effect of an infusion of DDAVP (0.3 µg/kg body weight) on thrombin generation in platelet-rich plasma (PRP) and platelet-poor plasma (PPP). Baseline thrombin generation in PRP was diminished both in the haemophilia A and vWD patients. It was normal in vWD plasma when sufficient procoagulant phospholipids were present, either via adding phospholipid vesicles to PPP or via scrambling of the platelet membrane with ionomycin in PRP. In haemophilia A plasma, thrombin generation did not normalize by providing procoagulant phospholipids. Treatment with DDAVP temporarily restored thrombin generation in PRP to normal in both diseases. To investigate the individual roles of von Willebrand factor (vWF) and factor VIII, we also studied the effect of factor VIII infusion on thrombin generation in a severe haemophilia patient. It appears that at a fixed normal vWF concentration, <25% factor VIII is sufficient for normal thrombin generation in PRP. At a sufficient factor VIII concentration, however, thrombin generation is still lower than normal in vWD patients; ∼40% of vWF is required for half-normal thrombin generation in PRP. It thus appears that vWF is also a clotting factor, in the sense that it is required for normal thrombin generation. This underlines the importance of the interaction between coagulation and the platelets in normal haemostasis. Thrombin generation in PRP appears to be a suitable test to reflect the combined function.Keywords
Funding Information
- Dutch Organization for Scientific Research (900-26-192)
This publication has 12 references indexed in Scilit:
- von Willebrand FactorPublished by Wiley ,2002
- Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand diseaseHaemophilia, 1998
- Thrombin, Fibrin and Platelets: a Resonance Loop in which von Willebrand Factor is a Necessary LinkThrombosis and Haemostasis, 1997
- Optimal intensity of oral anticoagulant therapy after myocardial infarctionJournal of the American College of Cardiology, 1996
- von Willebrand factorThe FASEB Journal, 1993
- The Manufacturing of the Recombinant Factor VIII, KogenateTransfusion Medicine Reviews, 1992
- Therapeutic target values in oral anticoagulation — Justification of Dutch policy and a warning against the so-called moderate-intensity regimensAnnals of Hematology, 1992
- Particle Enhanced Light Scattering ImmunoassayAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1992
- Staphylocoagulase-Binding Region in Human Prothrombin12The Journal of Biochemistry, 1985
- Thrombogenesis: Interaction of Blood Components with the Vessel WallPublished by Springer Nature ,1979